nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

15.04.2022 | Letter to the Editors

Transformation of invasive lung adenocarcinoma with ALK rearrangement into pulmonary sarcomatoid carcinoma

verfasst von: Xianjin Xie, Xudong Chen, Ningning Luo, Yingxue Qi, Mengmeng Li, Xiaoya Feng

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 8/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) improve outcomes for non-small-cell lung cancer (NSCLC) patients with ALK fusions. Nevertheless, ALK TKI resistance will inevitably occur. Histological transformation is one of the causes of TKI resistance in NSCLC. Reports of ALK-rearranged adenocarcinoma with histological transformation are limited.

Case presentation

A case of an invasive lung adenocarcinoma patient with ALK rearrangement who experienced histological transformation into sarcomatoid carcinoma after ALK TKI resistance is reported, and ALK fusion, MET amplification and TP53 mutation were detected after transformation.

Conclusions

This case first reported a patient with invasive lung adenocarcinoma harboring ALK rearrangement who underwent histological transformation into sarcomatoid carcinoma after ALK TKI resistance, and MET amplification might represent the cause. After transformation, the patient benefited from targeted therapy combined with chemotherapy, which represents a promising option for patients with sarcomatoid carcinoma transformation.

Nur mit Berechtigung zugänglich

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [published correction appears in CA Cancer J Clin. 2020 Jul;70(4):313]. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492CrossRefPubMed

Devarakonda S, Morgensztern D, Govindan R (2015) Genomic alterations in lung adenocarcinoma. Lancet Oncol 16(7):e342–e351. https://doi.org/10.1016/S1470-2045(15)00077-7CrossRefPubMed

Hsieh MS, Lin MW, Lee YH (2019) Lung adenocarcinoma with sarcomatoid transformation after tyrosine kinase inhibitor treatment and chemotherapy. Lung Cancer 137:76–84. https://doi.org/10.1016/j.lungcan.2019.08.029CrossRefPubMed

Kobayashi Y, Sakao Y, Ito S et al (2013) Transformation to sarcomatoid carcinoma in ALK-rearranged adenocarcinoma, which developed acquired resistance to crizotinib and received subsequent chemotherapies. J Thorac Oncol 8(8):e75–e78. https://doi.org/10.1097/JTO.0b013e318293d96fCrossRefPubMed

Levacq D, D’Haene N, de Wind R, Remmelink M, Berghmans T (2016) Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: a new mechanism of resistance to ALK inhibitors. Lung Cancer 102:38–41. https://doi.org/10.1016/j.lungcan.2016.10.012CrossRefPubMed

Marcoux N, Gettinger SN, O’Kane G et al (2019) EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes. J Clin Oncol 37(4):278–285. https://doi.org/10.1200/JCO.18.01585CrossRefPubMed

Matsui T, Sakakura N, Koyama S et al (2021) Comparison of surgical outcomes between invasive mucinous and non-mucinous lung adenocarcinoma. Ann Thorac Surg 112(4):1118–1126. https://doi.org/10.1016/j.athoracsur.2020.09.042CrossRefPubMed

Pelosi G, Gasparini P, Conte D et al (2016) Synergistic activation upon MET and ALK coamplification sustains targeted therapy in sarcomatoid carcinoma, a deadly subtype of lung cancer. J Thorac Oncol 11(5):718–728. https://doi.org/10.1016/j.jtho.2016.01.009CrossRefPubMed

Yang D, Li D, Dai Z et al (2021) Lung adenocarcinoma patients with novel ALK fusion variants and their clinical responses to ALK inhibitors. Cancer Commun (Lond) 41(2):183–186. https://doi.org/10.1002/cac2.12128CrossRef

Zheng J, Zhu J, Zhang K et al (2020) Temporal heterogeneity of resistance mechanisms to EGFR-TKI identified in a patient with lung adenocarcinoma and sarcomatoid transformation. Clin Lung Cancer 21(4):e255–e257. https://doi.org/10.1016/j.cllc.2020.02.003CrossRefPubMed

Titel: Transformation of invasive lung adenocarcinoma with ALK rearrangement into pulmonary sarcomatoid carcinoma
verfasst von: Xianjin Xie
Xudong Chen
Ningning Luo
Yingxue Qi
Mengmeng Li
Xiaoya Feng
Publikationsdatum: 15.04.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 8/2022
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-022-04022-0

Springer Medizin

Transformation of invasive lung adenocarcinoma with ALK rearrangement into pulmonary sarcomatoid carcinoma

Abstract

Background

Case presentation

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Background

Case presentation

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2022

Correction: Investigation of the protective effect of gel incorporating Eugenia jambolana leaf extract on 5-fluorouracil-induced oral mucositis: an animal study

An approach to p32/gC1qR/HABP1: a multifunctional protein with an essential role in cancer

First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study

Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer

Radiotherapy for glioblastoma patients with poor performance status

Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie